The British journal of ophthalmology · 2026
Incidence and treatment patterns of acute retinal necrosis: a nationwide population-based cohort study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Akada Masahiro, Hata Masayuki, Muraoka Yuki, Ishihara Kenji, Kadomoto Shin, Ueshima Hiroaki, Tamura Hiroshi, Tsujikawa Akitaka, Miyake Masahiro, Usui Yoshihiko
Аннотация
AIMS: To quantify nationwide incidence and contemporary treatment patterns of acute retinal necrosis (ARN).
METHODS: Retrospective cohort using Japan's National Database of Health Insurance Claims and Specific Health Checkups, which covers >95% of claims. New-onset ARN (2016-2022) was identified by ARN diagnostic codes plus antiviral therapy. Annual, age-specific and sex-specific incidence rates used governmental denominators; age-standardised rates used the WHO world standard. Surgical management (vitreoretinal surgery, silicone oil (SO)/perfluorocarbon (PFC) use, glaucoma surgery) was assessed up to 2 years after diagnosis.
RESULTS: Among 586 incident cases (313 men, 273 women), crude incidence was 0.066 (95% CI 0.061 to 0.072) per 100 000 person-years; the age-standardised rate was 0.040 per 100 000 person-years. Incidence rose with age, peaking at 70-74 years, and was consistently higher in men than in women. Vitreoretinal surgery occurred in 42.4% by 30 days and 59.4% by 365 days after diagnosis; 25.1% underwent ≥2 procedures within 1 year. SO or PFC was used in 40.8% by 1 year. Glaucoma surgery was uncommon (<2% by 2 years).
CONCLUSION: In the largest population-based study of ARN to date, nationwide incidence in Japan closely matched prior UK estimates, suggesting cross-system consistency in ARN epidemiology. Management was characterised by early, intensive surgery with frequent tamponade use and substantial reoperation, informing clinical triage and resource planning for this rare, vision-threatening condition.
METHODS: Retrospective cohort using Japan's National Database of Health Insurance Claims and Specific Health Checkups, which covers >95% of claims. New-onset ARN (2016-2022) was identified by ARN diagnostic codes plus antiviral therapy. Annual, age-specific and sex-specific incidence rates used governmental denominators; age-standardised rates used the WHO world standard. Surgical management (vitreoretinal surgery, silicone oil (SO)/perfluorocarbon (PFC) use, glaucoma surgery) was assessed up to 2 years after diagnosis.
RESULTS: Among 586 incident cases (313 men, 273 women), crude incidence was 0.066 (95% CI 0.061 to 0.072) per 100 000 person-years; the age-standardised rate was 0.040 per 100 000 person-years. Incidence rose with age, peaking at 70-74 years, and was consistently higher in men than in women. Vitreoretinal surgery occurred in 42.4% by 30 days and 59.4% by 365 days after diagnosis; 25.1% underwent ≥2 procedures within 1 year. SO or PFC was used in 40.8% by 1 year. Glaucoma surgery was uncommon (<2% by 2 years).
CONCLUSION: In the largest population-based study of ARN to date, nationwide incidence in Japan closely matched prior UK estimates, suggesting cross-system consistency in ARN epidemiology. Management was characterised by early, intensive surgery with frequent tamponade use and substantial reoperation, informing clinical triage and resource planning for this rare, vision-threatening condition.